Genentech's latest drug is a big — and expensive — option against muscle-wasting disease

The drug attacks a genetic disease that can kill kids by the age of 2 but also works on milder forms of the disease that affect adults.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.